These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9668194)

  • 1. The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications.
    Dannhardt G; Kohl BK
    Curr Med Chem; 1998 Aug; 5(4):253-63. PubMed ID: 9668194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.
    Jansen M; Dannhardt G
    Eur J Med Chem; 2003; 38(7-8):661-70. PubMed ID: 12932897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers.
    Hu LY; Guo J; Magar SS; Fischer JB; Burke-Howie KJ; Durant GJ
    J Med Chem; 1997 Dec; 40(26):4281-9. PubMed ID: 9435897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of excitatory amino acids in neuropathology].
    Wikinski SI; Acosta GB
    Medicina (B Aires); 1995; 55(4):355-65. PubMed ID: 8728878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor.
    Cai SX; Kher SM; Zhou ZL; Ilyin V; Espitia SA; Tran M; Hawkinson JE; Woodward RM; Weber E; Keana JF
    J Med Chem; 1997 Feb; 40(5):730-8. PubMed ID: 9057859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives.
    Fray MJ; Bull DJ; Carr CL; Gautier EC; Mowbray CE; Stobie A
    J Med Chem; 2001 Jun; 44(12):1951-62. PubMed ID: 11384240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,3-Dihydro-6,7-dichloro-pyrido[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity.
    Micheli F; Cugola A; Donati D; Missio A; Pecunioso A; Reggiani A; Tarzia G
    Bioorg Med Chem; 1997 Dec; 5(12):2129-32. PubMed ID: 9459010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMDA receptor antagonists and glycine site NMDA antagonists.
    Madden K
    Curr Med Res Opin; 2002; 18 Suppl 2():s27-31. PubMed ID: 12365826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective.
    Priestley T; Marshall GR; Hill RG; Kemp JA
    Br J Pharmacol; 1998 Aug; 124(8):1767-73. PubMed ID: 9756395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycine/NMDA receptor antagonists as potential CNS therapeutic agents: ACEA-1021 and related compounds.
    Cai SX
    Curr Top Med Chem; 2006; 6(7):651-62. PubMed ID: 16719807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The glycine site of the NMDA receptor--five years on.
    Kemp JA; Leeson PD
    Trends Pharmacol Sci; 1993 Jan; 14(1):20-5. PubMed ID: 8382885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
    Kornhuber J; Weller M
    Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de] quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de] quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor.
    Nagata R; Tanno N; Kodo T; Ae N; Yamaguchi H; Nishimura T; Antoku F; Tatsuno T; Kato T; Tanaka Y
    J Med Chem; 1994 Nov; 37(23):3956-68. PubMed ID: 7966156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
    Potschka H; Löscher W; Wlaź P; Behl B; Hofmann HP; Treiber HJ; Szabo L
    Br J Pharmacol; 1998 Nov; 125(6):1258-66. PubMed ID: 9863655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
    Leeson PD; Iversen LL
    J Med Chem; 1994 Nov; 37(24):4053-67. PubMed ID: 7990104
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.
    Palmer GC
    Curr Drug Targets; 2001 Sep; 2(3):241-71. PubMed ID: 11554551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Aminomethylquinoxaline-2,3-diones, Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists.
    Acklin P; Allgeier H; Auberson YP; Bischoff S; Ofner S; Sauer D; Schmutz M
    Bioorg Med Chem Lett; 1998 Mar; 8(5):493-8. PubMed ID: 9871605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.